Phase II Study of 5-azacytidine and Lintuzumab in Myelodysplastic Syndromes (MDS).

Trial Profile

Phase II Study of 5-azacytidine and Lintuzumab in Myelodysplastic Syndromes (MDS).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Azacitidine; Azacitidine; Lintuzumab
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2012 Lead trial centre changed from National Cancer Institute to Ohio State University Comprehensive Cancer Center as reported by ClinicalTrials.gov.
    • 12 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2010 Status changed from not yet recruiting to recruiting, according to a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top